List view / Grid view
In this exclusive interview, CEO of NewAmsterdam Pharma, Michael Davidson, offers insight into the low-density lipoprotein (LDL) cholesterol lowering therapeutic landscape and shares promising data from the company’s lead candidate, a cholesterol ester transfer protein (CETP) inhibitor.
The UK approval follows a Phase III study in which Leqvio® (inclisiran) reduced low-density lipoprotein cholesterol (LDL-C) by 55 percent.
Researchers have identified a possible association between use of statins and developing type 2 diabetes after following patients for 15 years...
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
A study has linked the use of statins to muscoskeletal adverse events, but that concomitant use of drugs did not cause changes in the onset of the events...
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
